Publicacións (185) Publicacións de TOMÁS PALOMO ÁLVAREZ

2024

  1. ANKK1 Is a Wnt/PCP Scaffold Protein for Neural F-ACTIN Assembly

    International Journal of Molecular Sciences, Vol. 25, Núm. 19

2023

  1. Failure of deactivation in bipolar disorder during performance of an fMRI adapted version of the Stroop task

    Journal of Affective Disorders, Vol. 329, pp. 307-314

  2. The gut-microbiota-brain axis in a Spanish population in the aftermath of the COVID-19 pandemic: microbiota composition linked to anxiety, trauma, and depression profiles

    Gut microbes, Vol. 15, Núm. 1, pp. 2162306

2021

  1. Activation and deactivation patterns in schizophrenia during performance of an fMRI adapted version of the stroop task

    Journal of Psychiatric Research, Vol. 144, pp. 1-7

2020

  1. Ankyrin repeat and kinase domain containing 1 gene, and addiction vulnerability

    International Journal of Molecular Sciences, Vol. 21, Núm. 7

  2. Hypothalamic-pituitary axis response to a 0.25-MG dexamethasone test in women with fibromyalgia

    Stress, Vol. 23, Núm. 3, pp. 284-289

  3. Parcel-guided rTMS for depression

    Translational Psychiatry, Vol. 10, Núm. 1

  4. Staging of depressive disorders: Relevance of resistance to treatment and residual symptoms

    Journal of Psychiatric Research, Vol. 129, pp. 234-240

  5. The relationships between sociodemographic, psychosocial and clinical variables

    Actas Espanolas de Psiquiatria, Vol. 48, Núm. 3, pp. 116-125

2019

  1. CIBERSAM: Ten years of collaborative translational research in mental disorders

    Revista de Psiquiatria y Salud Mental, Vol. 12, Núm. 1, pp. 1-8

  2. MCCB cognitive profile in Spanish first episode schizophrenia patients

    Schizophrenia Research, Vol. 211, pp. 88-92

  3. Resting state functional connectivity predictors of treatment response to electroconvulsive therapy in depression

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study

    The Lancet Psychiatry, Vol. 5, Núm. 10, pp. 797-807

2017

  1. The Addiction-Related Protein ANKK1 is Differentially Expressed During the Cell Cycle in Neural Precursors

    Cerebral Cortex, Vol. 27, Núm. 5, pp. 2809-2819

2016

  1. Conversion to dementia in mild cognitive impairment diagnosed with DSM-5 criteria and with Petersen's criteria

    Acta Psychiatrica Scandinavica, Vol. 133, Núm. 5, pp. 378-385

  2. Elevated midline-parietal gamma band noise power in schizophrenia but not in bipolar patients

    European Archives of Psychiatry and Clinical Neuroscience, Vol. 266, Núm. 8, pp. 743-753

  3. Facial affect recognition in early and late-stage schizophrenia patients

    Schizophrenia Research, Vol. 172, Núm. 1-3, pp. 177-183

  4. Staging cognitive impairment and incidence of dementia

    Epidemiology and Psychiatric Sciences, Vol. 25, Núm. 6, pp. 562-572

  5. The Addiction-Related Gene Ankk1 is Oppositely Regulated by D1R- and D2R-Like Dopamine Receptors

    Neurotoxicity Research, Vol. 29, Núm. 3, pp. 345-350

  6. The microbiota and gut-brain axis: Contributions to the immunopathogenesis of schizophrenia

    Current Pharmaceutical Design, Vol. 22, Núm. 40, pp. 6122-6133